Hemorrhagic stroke in the SPARCL study

Stroke

Volumn 39, Issue 11, 2008, Pages

  Mascitelli, Luca ^a   Pezzetta, Francesca ^b   Goldstein, Mark R ^c  

^a Medical Service   (Italy)

^b Ospedale Civile di Tolmezzo   (Italy)

^c Fountain Medical Court ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; PYRROLE DERIVATIVE;

ACCURACY; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOLLOW UP; HEMORRHAGIC STROKE; HUMAN; LETTER; PRIORITY JOURNAL; RECANALIZATION; RECURRENT DISEASE; SENSITIVITY ANALYSIS; SEX DIFFERENCE; STROKE; TRANSIENT ISCHEMIC ATTACK; BLOOD; BRAIN HEMORRHAGE; FEMALE; MALE; NOTE; PATHOLOGY; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; FEMALE; HEPTANOIC ACIDS; HUMANS; INTRACRANIAL HEMORRHAGES; LIPOPROTEINS, LDL; MALE; PYRROLES; RISK FACTORS; STROKE;

EID: 55749103370     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.532309     Document Type: Letter

References (6)

1. Goldstein LB, Amarenco P, Lamonte M, Gilbert S, Messig M, Callahan A, Hennerici M, Sillesen H, Welch KM; on behalf of the SPARCL Investigators. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Stroke. 2008;39:2444-2448.
2. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High- dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
3. Goldstein LB, Amarenco P, Szarek M, Callahan A III, Hennerici M, Sillesen H, Zivin JA, Welch KM; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70:2364-2370.
4. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke. 2008;39:497-502.
5. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebro-vascular disease or other high-risk conditions. Lancet. 2004;363:757-767.
6. Bang OY, Saver JL, Liebeskind DS, Starkman S, Villablanca P, Salamon N, Buck B, Ali L, Restrepo L, Vinuela F, Duckwiler G, Jahan R, Razinia T, Ovbiagele B. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology. 2007;68:737-742. [Erratum in: Neurology. 2007;68:1547.]